The PolyPeptide Group employs approximately 750 staff at sites in Belgium, France, India, Sweden and the USA. The PolyPeptide Group is the world’s largest independent contract manufacturer of therapeutic peptides. The privately-held organization manufactures over one third of all approved peptide drug substances and accounts for over 30% of the sales of outsourced peptide therapeutics worldwide. The Group offers its customers an almost unprecedented long-term security of supply with six GMP facilities worldwide and an exclusive focus on pharmaceutical peptide manufacture.
NEC OncoImmunity is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neo-antigens for personalized cancer immunotherapy. NEC OncoImmunity is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in clinically actionable timeframe.
Cayman’s Immunology and Cellular Metabolism Services can complement your drug discovery efforts. Our Immunopeptidome Profiling Services enable deep sequencing analysis of MHC associated peptides by LC-MS/ MS, allowing neoantigen identification in cell lines and tumor tissue. Our Cellular Metabolism Services measure the metabolic response of cells to therapeutics under a wide range of customizable in vitro metabolic environments. Cayman’s expertise in cell culture, immunoassays, antibodies, and assay development provides a complete solution for your research needs.
Almac has been supplying peptides to the research community and for clinical trials for over 20 years. The field of personlised cancer vaccines requires a new manufacturing paradigm to ensure high throughput manufacture of multiple neoantigens in an appropriate timescale to the required quality and regulatory standards. Almac has created a unique offering to meet all of those demands, which can be tailored to meet specific client needs.
Pepscan is able to guide and timely provide you with personalized neoantigen peptides of the highest quality for your clinical trial. We build on our role as critical partner in multiple personalized neoantigen peptide clinical trials and know what it takes to be a world-class partner in this area. Flexibility is an integral part of our GMP-graded state-of the art facility’s workflows resulting in reliable delivery of neoantigen peptides in as little as three weeks.